Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
80 Cards in this Set
- Front
- Back
|
narcotine |
exo organic opium alkaloid |
|
|
papavernie |
exo organic opium alkaloid |
|
|
morphine |
exo organic opium alkaloid |
|
|
codeine |
exo organic opium alkaloid |
|
|
thebain |
exo organic opium alkaloid |
|
|
oxymorphone |
modified opiate numorphon |
|
|
diacetylmorphine |
modified opiate heroin |
|
|
oxycodone |
modified opiate percodan oxycotin |
|
|
hydrocodone |
modified opiate dilaudid |
|
|
hydromorphone |
modified opiate vicodin |
|
|
buprenophrine |
synthetic opiates (piperidine andgesies) buprenex partial ago |
|
|
methadone |
synthetic opiates (piperidine andgesies) dolophine |
|
|
meperidine |
synthetic opiates (piperidine andgesies) demerol trtment of addiction |
|
|
propoxyphene |
synthetic opiates (piperidine andgesies) dorvone |
|
|
fentanyl |
synthetic opiates (piperidine andgesies) short acting |
|
|
sefentanil |
synthetic opiates (piperidine andgesies) short acting |
|
|
nalaxone |
opiate ant overdose treatment |
|
|
naltrexone |
opiate ant overdose treatment |
|
|
diprenorphine |
opiate ant overdose treatment |
|
|
withdrawal: early symptoms |
watery eyes, runny nose, yawning no apetitie, anxiety, irritability, insomnia, rapid increase in AC activity |
|
|
withdrawal: longer duration |
tremors hallucinations, panic, chills, sweating, cramps, nasea wretching high rate of recividism |
|
|
major categories of controlled substances: stimulants |
nicotine, caffeine, ephedrine, cocaine, amphetamines, designer drugs |
|
|
major categories of controlled substances: depressants |
ethanol, barbituates, BDZ, opiates, PCP, ketamine |
|
|
major categories of controlled substances: hallucinogens/psychoactives |
marijuana, hash, peyote, LSD, PCP/ketamine, psilocybin, DD(exstacy) |
|
|
major categories of controlled substances: anabolic steroids |
androgens |
|
|
Drug enforcement: DEA (justice) |
-federal concentration on trafficking (international and interstate), diversion, elimination of foreign growers |
|
|
Drug enforcement: ATF (treasurey) |
-federal concentration on domestic prodxn, growers, theoretical revenue source |
|
|
DPS |
- state - involved all levels, including low level dealers and useres |
|
|
Sheriff |
-county all levels including low level dealers and users |
|
|
police |
-local - all levels inlcuding low level dealers and users |
|
|
DEA: CSA |
-controlled substances act -title 2 of he comprehensive dug abuse prevention and contrl act of 1970 is the legal foundation of the gov. fight against abuse of drugs and other substances |
|
|
Federal Drugs laws: how many schedules? |
5 |
|
|
Federal drug laws: placed under schedules based on? |
1. potential for abuse 2. Medical use 3.Safety/Dependence liability |
|
|
Drug laws evauated: tabacco |
formal scheduling: potential for abuse
create hazard for health/safety not medical -tabacco should be a felony drug ethanol as well |
|
|
federal drug schedules: 1 |
diactylmorphine, methaqualone, LSD, POT,MDMA,peyote, psilocybin-->lack of accepted safety |
|
|
Federal drug schedules: 2 |
morphine, cocoaine, methadone, hydrocodone, methamphetamine, --> high potential for abuse, accepted med use, may lead to sever psychological or physical dependecne |
|
|
federal drug laws: schedule 3 |
anabolic steroids, codeine/hydrocodone w tylenol, ketamine, ---> potential fo rabuse, currently accept med use, moderate/ decreased phys dependence |
|
|
federal drug laws: schedule 4 |
BDZ's, anxiolytic drugs decreased potential abuse, aceept med use, decerased psychological and physical dependence |
|
|
federal drug laws: schedule 5 |
cough syrup with codein decreased potential abuse, accepted med use, imited physical or psychological dependence |
|
|
Variability in enforcement: nicotine |
stimulant no sale to minors |
|
|
Variability in enforcement: cocaine |
s2 stimulant |
|
|
Variability in enforcement: amphetamine |
stimulant s2 |
|
|
Variability in enforcement: DD's |
s1 stimulant |
|
|
Variability in enforcement: Etoh |
depressant no sale to minors |
|
|
Variability in enforcement: opiates |
depressants s1,s2,s3,s4,s5 |
|
|
Variability in enforcement: barbituates |
depressants s2,s3,s4 |
|
|
Variability in enforcement: BDZ |
depressants s4 |
|
|
Variability in enforcement: methaqualone |
depressants s1 |
|
|
Variability in enforcement: DD |
psychedelic drugs s1 |
|
|
Variability in enforcement: LSD |
psychedlic drugs s1 |
|
|
Variability in enforcement:peyote |
psychedelic drugs s1 |
|
|
Variability in enforcement: marijuana |
psychedelic drugs s1*** legal in WA, CO |
|
|
Variability in enforcement: ketamine |
psychedelic drug s2 |
|
|
Variability in enforcement:PCP |
psychedelic drug s2 |
|
|
Variability in enforcement: anabolic steroids |
s3 |
|
|
stimulants : health risks |
sudden arythmias, cardiac failure, multiple organ failure, risk of acute psychosis w/ high doses/chronic use, percieved better performance not neccesarily tre |
|
|
stimulants: physical dependence |
strong risk, once developed physical withdrawal begins within hours after last does, withdrawal less severe than opiates |
|
|
stimulants: psychological dependece |
strong risk high recividism for former users |
|
|
opiates: health risks |
over dose, potentially fatal coma, respiratory depresson, emesis, diseases from needle sharing, malnutrituion bc of decreased apetite, |
|
|
opiates: physical dependence |
strong risk, withdrawal within hs of last does |
|
|
opiates: psychological dependence |
reported for piperidine deritives (PCP, ketamins, etc) probable evidence for marijuana for some individuals |
|
|
cannabis: health risks |
smoking related respirator problems (can be more intesne then tabacco) mild immunosupression, stabalizes with chronic use, problems associated with adulterants, herbicides, |
|
|
cannabis physical dependence |
unsure |
|
|
cannabis: psychological dependence |
varies widely by individual, length of use, dosage |
|
|
cannabis: clinical uses |
antiemtic/nasea supresant (cemo) relief o ocular pressure in glaucoma treatment of lymphomas anxiolytic |
|
|
cannabinoid receptor: CB1 |
presyn in CNS, glial, also in lungs, testes, uteres`
|
|
|
Cannanbinoid receptor: CB2 |
immune sys, glial |
|
|
cannanbinoid receptor:GPR55 |
nociceptors, vascular smooth muscle |
|
|
anandamide |
endo ago CB1, CB2 |
|
|
noladin |
endo ago CB2. gpr55 |
|
|
THC |
exo ago CB1, CP2, GPR55 |
|
|
Dronabinol |
exo ago CB1, CB2, GPR55 |
|
|
Arvanil |
specific ago CB1 |
|
|
CB1, CB2 g prot |
Gi |
|
|
GPR55 g prot |
G13 |
|
|
bp subunits CB1 |
inhibit VDCC, activate GIRKS |
|
|
Gs |
D1,D5 5HT 4,6,7 Beta 1,2,3 H2 |
|
|
Gi |
D2,3,4 5HT1-A,B,D,E,F Alpha 2A,B,C H3,4 m2,4 mglur- 2,3,4,6,7,8 |
|
|
Gi/Go |
GabaB |
|
|
Gq |
5HT2-A,B,C alpha1-A,B,D H1 M1,3,5 mglur1,5 |
